HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (56) Citing Articles via Google Scholar Google Scholar Articles by Rifai, N. Articles by Ridker, P. M. Search for Related Content PubMed PubMed Citation Articles by Rifai, N. Articles by Ridker, P. M. Related Collections Proteomics and Protein Markers Lipids, Lipoproteins, and Cardiovascular Risk Factors

Population Distributions of C-reactive Protein in Apparently Healthy Men and Women in the United States: Implication for Clinical Interpretation

¹ Department of Laboratory Medicine, Children’s Hospital, Boston, MA 02115

² Center of Cardiovascular Disease Prevention and
³ Division of Cardiovascular Disease, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115

^aaddress correspondence to this author at: Children’s Hospital, Department of Laboratory Medicine, 300 Longwood Ave., Boston, MA 02115; fax 617-713-4347, e-mail nader.rifai{at}tch.harvard.edu

Measurement of the acute-phase reactant C-reactive protein (CRP) has been used historically in the diagnosis and monitoring of active infection or inflammation. Recent prospective epidemiologic studies have demonstrated that CRP, at concentrations within the reference interval, is a strong predictor of myocardial infarction (1)(2)(3), stroke (1)(2)(4), sudden cardiac death (5), and peripheral arterial disease (6) in apparently healthy adults. High-sensitivity methods that are capable of reliably measuring CRP concentrations 0.15 mg/L (approximately the first and second percentiles of CRP distribution in healthy adults) have, therefore, been developed (7)(8). Furthermore, an algorithm for risk assessment of future coronary events that combines both CRP concentration and total cholesterol:HDL-cholesterol ratio has been proposed (9). According to this algorithm, an individual’s risk can be estimated with use of quintiles of CRP and lipids derived from ongoing population-based surveys.

Because high-sensitivity methods have only recently become available, the frequency distributions of CRP in apparently healthy US adults have not been carefully examined. Such information is useful in determining the most appropriate CRP cutpoints for the risk assessment algorithm in men and women. In this report, we describe the frequency distribution of CRP in 22 403 US adults and propose new CRP cutpoints for clinical interpretation.

CRP measurement was performed in 22 403 apparently healthy individuals participating in the Physicians’ Health Study (PHS), the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), the Women’s Health Initiative (WHI), and the Women’s Health Study (WHS). Details of these studies have been published elsewhere (10)(11)(12)(13). To avoid the issue of confounding by disease outcome, we evaluated only those individuals who were free of cardiovascular disease at study entry and remained free from disease during follow-up. To avoid confounding by drugs, we eliminated those women taking hormone replacement therapy. In total, our study included 15 770 women not taking hormone replacement therapy from the WHS and 348 from the WHI, 5742 men and women from AFCAPS/TexCAPS, and 543 men from the PHS. Participants’ ages ranged from 40 to 84 years. Plasma samples for the WHS were stored in liquid nitrogen, and those for the other three studies were stored at -70 to -80 °C until analysis.

In this study, CRP was measured in various cohorts by three different methods. In the PHS, CRP concentration was determined by an in-house competitive ELISA with use of polyclonal anti-CRP antibodies (Calbiochem-Novabiochem) and a calibrator that was traceable to WHO Reference Material 85-506 (14). The run-to-run imprecision, reflected by the CVs, at CRP concentrations of 1.05, 2.08, and 2.52 mg/L was 5.7%, 5.5%, and 6.8%, respectively. In the AFCAPS/TexCAPS and WHI studies, CRP was measured by a particle-enhanced assay performed on the BNII Nephelometer (Dade Behring) (7). The assay used monoclonal anti-CRP antibodies and a calibrator that was traceable to the WHO Reference Material. The run-to-run imprecision at CRP concentrations of 0.15, 0.49, and 1.90 mg/L was 4.9%, 6.4%, and 5.8%, respectively. In the WHS, CRP was measured by latex-enhanced reagents from Denka-Seiken on a Hitachi 911 automated analyzer (Roche Diagnostics) (8). The assay used monoclonal anti-CRP antibodies and a calibrator that was traceable to the WHO Reference Material. The run-to-run imprecision at CRP concentrations of 0.71, 0.41, and 1.88 mg/L was 5.1%, 3.3%, and 2.5%, respectively.

We have previously demonstrated that the three methods are analytically and clinically comparable. With the Dade Behring as the comparison method, the in-house ELISA gave a slope of 0.99 and an intercept of 0.36 mg/L (r = 0.95; S_y|x = 0.14; n = 288), and the Denka Seiken method gave a slope of 0.97 and an intercept of -0.05 mg/L (r = 0.995; S_y|x = 0.31; n = 388) (7)(8).

The distributions of CRP for both men and women were highly skewed to the right, and <5% of men and women had CRP >10 mg/L, findings consistent with earlier reports (15)(16)(17). In our largest cohort (WHS), we demonstrated only a slight change in CRP concentration with age: median CRP concentrations for individuals 45–54, 55–64, 65–74, and 75 years of age were 1.31, 1.89, 1.99, 1.52, and 1.52 mg/L, respectively (18). In addition, the median CRP concentrations seen in our cohorts are comparable to those reported from other populations (15)(16)(17)(19). The frequency distribution of CRP values for these apparently healthy US men and women not taking hormone replacement therapy were comparable (Table 1A and 1B ). This observation has a substantial clinical implication because it clearly demonstrates that a single set of cutpoints for risk assessment of future coronary events can be used for both genders. A similar observation regarding the similarity of CRP distribution among Scottish men and women has been reported (15). However, in a German cohort, women tended to have slightly, but significantly higher, CRP concentrations compared with men, which was attributed to estrogen use (15). Hormone replacement therapy, whether it is with estrogen alone or in combination with progestin, is known to significantly increase CRP concentration (20)(21). On the basis of findings from the WHI (22) and the Heart and Estrogen/Progestin Replacement Study (23), hormone replacement therapy is not currently recommended for women with or without heart disease for the purpose of reducing future risk of coronary events. It therefore is imperative that future studies that examine the population distribution of CRP exclude women receiving hormone replacement therapy.

As indicated earlier, the initially proposed algorithm for assessing future coronary risk used quintiles of CRP and total cholesterol:HDL-cholesterol ratio. Recently, it has been shown that quintiles and tertiles of CRP are similarly associated with future risk of coronary event (24). Furthermore, when combined with CRP, the ability of LDL-cholesterol to predict cardiovascular disease was comparable to that of the total cholesterol:HDL-cholesterol ratio (18). Therefore, for ease of clinical interpretation, a more simplified set of cutpoints that are based on approximate tertiles of the US population (<1.0, 1.0–3.0, >3.0 mg/L) could be used (25). These cutpoints have the advantage of being easy to remember and, when added to LDL-cholesterol cut points of <1300, 1300–1600, and >1600 mg/L, can be used in an algorithm for risk assessment of cardiovascular heart disease in primary prevention (Fig. 1 ). The LDL-cholesterol cutpoints used are those recommended by the National Cholesterol Education Program (NCEP).

View larger version (18K): [in this window] [in a new window]   Figure 1. Proposed algorithm for risk assessment of coronary heart disease in men and women. CRP cutpoints are approximate tertiles of US adult population, and LDL-cholesterol cutpoints are those of the National Cholesterol Education Program. Presented risk estimates are not adjusted for other coronary heart disease risk factors.

The limitations of this study deserve mention. The CRP concentrations in the examined cohorts were measured by three different methods. We previously demonstrated that the three methods used were analytically and clinically comparable (7)(8). All three methods used calibrators that are traceable to the WHO Reference Materials and were able to classify individuals comparably into quartiles of risk. The consistency in the population distributions among the various cohorts despite the use of three different methods is a good indication of the comparability of these assays and further strengthens our findings.

Some of the study samples (PHS, AFCAPS/TexCAPS, WHI) were stored at -70 °C to -80 °C, and others (WHS) were stored in liquid nitrogen for several years before analysis. CRP has long been recognized as a very stable protein. In fact, no significant change was seen in CRP concentrations of samples stored at -70 °C for up to 20 years (26). In-house data show only a minor effect of storage in liquid nitrogen for 6 months on CRP values of samples collected from apparently healthy individuals [mean (SD) for fresh samples, 4.3 (4.9) mg/L vs 4.1 (4.5) mg/L for frozen samples; n = 23]. The comparable CRP distribution seen among the various examined groups attests to the stability of this protein when stored at different temperatures of -70 °C or lower.

The examined populations consisted predominantly of Caucasians, thus raising the question as to whether the recommended cutpoints and risk estimates may be expanded to other ethnic groups. The CRP distributions reported here were not only comparable to those reported from European populations but also to those for Japanese men (15)(17)(19). Japanese women, however, seem to have lower CRP values (17). No data currently exist regarding the distribution of CRP in African-American and Hispanic adult populations. Clearly, studies are urgently needed to determine whether ethnic-dependent CRP cutpoints are needed for clinical decision-making.

In conclusion, we have demonstrated a similar distribution of CRP concentrations among apparently healthy US men and women. In addition, we have proposed a new set of cutpoints to be used clinically in assessing the risk of future coronary events in both genders.

Acknowledgments

Dr. Ridker is named as a co-inventor on patents filed by Brigham and Women’s Hospital that pertain to inflammatory markers and cardiovascular disease.

References

1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published erratum appears in N Engl J Med 1997;337:356]. N Engl J Med 1997;336:973-979.[Abstract/Free Full Text]
2. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.[Abstract/Free Full Text]
3. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242.[Abstract/Free Full Text]
4. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001;32:2575-2579.[Abstract/Free Full Text]
5. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002;105:2595-2599.[Abstract/Free Full Text]
6. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-2485.[Abstract/Free Full Text]
7. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45:2136-2141.[Abstract/Free Full Text]
8. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 2001;47:418-425.[Abstract/Free Full Text]
9. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem 2001;47:28-30.[Free Full Text]
10. Physician’s Health Study: aspirin and primary prevention of coronary heart disease. N Engl J Med 1989;321:1825-1828.[Web of Science][Medline] [Order article via Infotrieve]
11. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622.[Abstract/Free Full Text]
12. Design of the Women’s Health Initiative clinical trial and observational study. The Women’s Health Initiative Study Group. Control Clin Trials 1998;19:61-109.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
13. Buring JE, Hennekens CH. The Women’s Health Study: summary of the study design. J Myocard Ischemia 1992;4:27-29.
14. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-58.[Abstract/Free Full Text]
15. Hutchinson WL, Koenig W, Frohlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 2000;46:934-938.[Abstract/Free Full Text]
16. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998;35:745-753.
17. Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 2001;153:1183-1190.[Abstract/Free Full Text]
18. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.[Abstract/Free Full Text]
19. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996;312:1061-1065.[Abstract/Free Full Text]
20. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 1999;100:717-722.[Abstract/Free Full Text]
21. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-716.[Abstract/Free Full Text]
22. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-333.[Abstract/Free Full Text]
23. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.[Abstract/Free Full Text]
24. Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-369.[Free Full Text]
25. Pearson TA, Mensah GA, Alexander W, Anderson JL, Cannon RO, III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.[Free Full Text]
26. Wilkins J, Gallimore JR, Moore EG, Pepys MB. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem 1998;44:1358-1361.[Free Full Text]

The following articles in journals at HighWire Press have cited this article:

				D. E. Chiriboga, Y. Ma, W. Li, E. J. Stanek III, J. R. Hebert, P. A. Merriam, E. S. Rawson, and I. S. Ockene Seasonal and Sex Variation of High-Sensitivity C-Reactive Protein in Healthy Adults: A Longitudinal Study Clin. Chem., February 1, 2009; 55(2): 313 - 321. [Abstract] [Full Text] [PDF]

				P. O. Collinson Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death: Just Another Brick in the Wall? Clin. Chem., February 1, 2009; 55(2): 203 - 205. [Full Text] [PDF]

				J. L. Shifren, N. Rifai, S. Desindes, M. McIlwain, G. Doros, and N. A. Mazer A Comparison of the Short-Term Effects of Oral Conjugated Equine Estrogens Versus Transdermal Estradiol on C-Reactive Protein, Other Serum Markers of Inflammation, and Other Hepatic Proteins in Naturally Menopausal Women J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1702 - 1710. [Abstract] [Full Text] [PDF]

				C. Marsik, L. Kazemi-Shirazi, T. Schickbauer, S. Winkler, C. Joukhadar, O. F. Wagner, and G. Endler C-Reactive Protein and All-Cause Mortality in a Large Hospital-Based Cohort Clin. Chem., February 1, 2008; 54(2): 343 - 349. [Abstract] [Full Text] [PDF]

				C. P. Hersh, D. T. Miller, D. J. Kwiatkowski, and E. K. Silverman Genetic determinants of C-reactive protein in COPD Eur. Respir. J., December 1, 2006; 28(6): 1156 - 1162. [Abstract] [Full Text] [PDF]

				C. W. Hogue Jr, T. Hershey, D. Dixon, R. Fucetola, A. Nassief, K. E. Freedland, B. Thomas, and K. Schechtman Preexisting cognitive impairment in women before cardiac surgery and its relationship with C-reactive protein concentrations. Anesth. Analg., June 1, 2006; 102(6): 1602 - 1608. [Abstract] [Full Text] [PDF]

				P. C. Kao, S.-C. Shiesh, and T.-J. Wu Serum C-reactive protein as a marker for wellness assessment. Ann. Clin. Lab. Sci., March 1, 2006; 36(2): 163 - 169. [Abstract] [Full Text] [PDF]

				K. S Kornman Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging Am. J. Clinical Nutrition, February 1, 2006; 83(2): 475S - 483S. [Abstract] [Full Text] [PDF]

				E. M. Crimmins and C. E. Finch Infection, inflammation, height, and longevity PNAS, January 10, 2006; 103(2): 498 - 503. [Abstract] [Full Text] [PDF]

				A. Stefanska, G. Sypniewskay, and L. Senterkiewicz Inflammatory Markers and Cardiovascular Risk in Healthy Polish Women across the Menopausal Transition Clin. Chem., October 1, 2005; 51(10): 1893 - 1895. [Full Text] [PDF]

				D. E. Laaksonen, L. Niskanen, K. Nyyssonen, K. Punnonen, T.-P. Tuomainen, and J. T. Salonen C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study Eur. Heart J., September 1, 2005; 26(17): 1783 - 1789. [Abstract] [Full Text] [PDF]

				A. Khera, D. K. McGuire, S. A. Murphy, H. G. Stanek, S. R. Das, W. Vongpatanasin, F. H. Wians Jr, S. M. Grundy, and J. A. de Lemos Race and Gender Differences in C-Reactive Protein Levels J. Am. Coll. Cardiol., August 2, 2005; 46(3): 464 - 469. [Abstract] [Full Text] [PDF]

				Y. Song, P. M. Ridker, J. E. Manson, N. R. Cook, J. E. Buring, and S. Liu Magnesium Intake, C-Reactive Protein, and the Prevalence of Metabolic Syndrome in Middle-Aged and Older U.S. Women Diabetes Care, June 1, 2005; 28(6): 1438 - 1444. [Abstract] [Full Text] [PDF]

				M. Di Napoli, M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H. C.A. Emsley, S. Forconi, S. J. Hopkins, L. Masotti, et al. Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke: A Statement for Health Care Professionals From the CRP Pooling Project Members Stroke, June 1, 2005; 36(6): 1316 - 1329. [Abstract] [Full Text] [PDF]

				L. Anderson Candidate-based proteomics in the search for biomarkers of cardiovascular disease J. Physiol., February 15, 2005; 563(1): 23 - 60. [Abstract] [Full Text] [PDF]

				G. L. Myers, N. Rifai, R. P. Tracy, W. L. Roberts, R. W. Alexander, L. M. Biasucci, J. D. Catravas, T. G. Cole, G. R. Cooper, B. V. Khan, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Report From the Laboratory Science Discussion Group Circulation, December 21, 2004; 110(25): e545 - e549. [Full Text] [PDF]

				M. Lambert, E. E. Delvin, G. Paradis, J. O'Loughlin, J. A. Hanley, and E. Levy C-Reactive Protein and Features of the Metabolic Syndrome in a Population-Based Sample of Children and Adolescents Clin. Chem., October 1, 2004; 50(10): 1762 - 1768. [Abstract] [Full Text] [PDF]

				S. Melamed, A. Shirom, S. Toker, S. Berliner, and I. Shapira Association of Fear of Terror With Low-Grade Inflammation Among Apparently Healthy Employed Adults Psychosom Med, July 1, 2004; 66(4): 484 - 491. [Abstract] [Full Text] [PDF]

				E. S. Ford, W. H. Giles, A. H. Mokdad, and G. L. Myers Distribution and Correlates of C-Reactive Protein Concentrations among Adult US Women Clin. Chem., March 1, 2004; 50(3): 574 - 581. [Abstract] [Full Text] [PDF]

				A. J. MacGregor, J. R. Gallimore, T. D. Spector, and M. B. Pepys Genetic Effects on Baseline Values of C-Reactive Protein and Serum Amyloid A Protein: A Comparison of Monozygotic and Dizygotic Twins Clin. Chem., January 1, 2004; 50(1): 130 - 134. [Abstract] [Full Text] [PDF]

				N. Khuseyinova, A. Imhof, G. Trischler, D. Rothenbacher, W. L. Hutchinson, M. B. Pepys, and W. Koenig Determination of C-Reactive Protein: Comparison of Three High-Sensitivity Immunoassays Clin. Chem., October 1, 2003; 49(10): 1691 - 1695. [Full Text] [PDF]

				T. B. Ledue and N. Rifai Preanalytic and Analytic Sources of Variations in C-reactive Protein Measurement: Implications for Cardiovascular Disease Risk Assessment Clin. Chem., August 1, 2003; 49(8): 1258 - 1271. [Abstract] [Full Text] [PDF]

This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (56) Citing Articles via Google Scholar Google Scholar Articles by Rifai, N. Articles by Ridker, P. M. Search for Related Content PubMed PubMed Citation Articles by Rifai, N. Articles by Ridker, P. M. Related Collections Proteomics and Protein Markers Lipids, Lipoproteins, and Cardiovascular Risk Factors